glucarpidase

Glucarpidase is a recombinant bacterial enzyme (carboxypeptidase G2) used as an antidote to reduce toxic plasma methotrexate concentrations in patients with delayed methotrexate clearance due to impaired renal function. It is produced by genetically modified Escherichia coli and consists of a 390-amino acid homodimer protein. Glucarpidase works by hydrolyzing the carboxyl-terminal glutamate residue from folic acid and classical antifolates such as methotrexate, converting methotrexate into its inactive metabolites 4-deoxy-4-amino-N10-methylpteroic acid (DAMPA) and glutamate. This provides an alternative non-renal route for methotrexate elimination, rapidly reducing plasma levels of the drug and mitigating toxicity risks in both adult and pediatric cancer patients[1][2][3][6][8].

Brand names

Voraxaze

Other names

carboxypeptidase G2